# Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC

> **NCT06706219** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer (Stage III)

## Interventions

- **DRUG:** Sacituzumab tirumotecan plus toripalimab

## Key facts

- **NCT ID:** NCT06706219
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-10
- **Primary completion:** 2028-11-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06706219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06706219, "Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06706219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*